3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
6
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Neoplasm Metastasis
2
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neoplasms
1
Meningioma
1
Malignant Female Reproductive System Neoplasm
1
Hemangiosarcoma
1
HER2-positive Breast Cancer
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Ependymoma
1
Endometrial Neoplasms
1
Disease Progression
1
Colonic Neoplasms
1
Carcinoma, Lobular
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
lutetium Lu 177 dotatate
2
Temozolomide
2
ONC206
2
Etoposide
2
Cyclophosphamide
2
Bevacizumab
2
olaparib
1
neratinib
1
ibrutinib
1
fenofibric acid
1
etoposide phosphate
1
brigatinib
1
Watchful Waiting
1
Thalidomide
1
Restraint, Physical
1
Radiotherapy
1
Radiation
1
Magnetic Resonance Spectroscopy
1
Linear Energy Transfer
1
Irinotecan
1
Elasticity Imaging Techniques
1
Cytarabine
1
Celecoxib
1
Automobiles
1
1-methyltryptophan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Ependymoma
×
neratinib
×
Clear all
NCT04374305
2026-05-06
INTUITT-NF2
Massachusetts General Hospital
Phase 2
Recruiting
109 enrolled